- Home
- CTO vs LAB Comparison
CTO vs LAB Comparison
Compare CTO & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTO | LAB |
|---|---|---|
| Founded | 1902 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Laboratory Analytical Instruments |
| Sector | Real Estate | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 586.6M | 488.4M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | CTO | LAB |
|---|---|---|
| Price | $17.75 | $1.48 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 2 |
| Target Price | ★ $22.00 | $1.35 |
| AVG Volume (30 Days) | 246.9K | ★ 1.6M |
| Earning Date | 02-19-2026 | 02-25-2026 |
| Dividend Yield | ★ 8.56% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $146,948,000.00 | ★ $169,737,000.00 |
| Revenue This Year | $21.24 | N/A |
| Revenue Next Year | $5.46 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 23.84 | ★ 79.77 |
| 52 Week Low | $15.07 | $0.92 |
| 52 Week High | $20.88 | $1.72 |
Technical Indicators
Market Signals| Indicator | CTO | LAB |
|---|---|---|
| Relative Strength Index (RSI) | 42.74 | 48.94 |
| Support Level | $17.81 | $1.50 |
| Resistance Level | $18.18 | $1.67 |
| Average True Range (ATR) | 0.32 | 0.10 |
| MACD | -0.09 | -0.00 |
| Stochastic Oscillator | 6.37 | 54.66 |
Price Performance
Historical ComparisonAbout CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties comprised of approximately 2.7 million square feet in diversified markets in the United States. Its portfolio of assets consists of Income Properties Portfolio, management services, Commercial Loan and Investments.
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.